Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 936 trials

New Treatment for Limbal Stem Cell Deficiency: Oral Mucosa Cells

We are testing a new method using cultured cells from the mouth to help people with limbal stem cell deficiency. This study aims to see if this treatment can improve eye health and vision.

Limbal Stem Cell Deficiency>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Early Alzheimer's Disease: NIO752 Study

We are investigating a new medication for people with early Alzheimer's disease to assess its safety and how it works in the body. This study aims to gather important information about the treatment's effects.

Alzheimer's Disease>2 yearsSafety phase (I)Neurology

Advanced Cancers: FS222 Antibody Treatment

We are evaluating a new antibody medication for individuals with advanced cancers to see if it is safe and effective. This study aims to understand how well FS222 works in treating these conditions.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Osteoarthritis of the Knee: SAR446959 Study

We are investigating a new treatment to see if it is safe and well-tolerated by people with knee osteoarthritis. This study aims to gather important information about its effects on participants.

Osteoarthritis1-2 yearsSafety phase (I)Internal MedicineOrthopedics and Traumatology

Advanced Cancer: BI 765063 and BI 770371 Study

We are studying how two new drugs are taken up in tumors of people with different types of advanced cancer who are also receiving Ezabenlimab. This research may help improve future cancer treatments.

Non-Small Cell Lung CancerMelanomaHead and Neck Squamous Cell CarcinomaSafety phase (I)Oncology

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Melanoma Treatment: TILT-123 and Chemotherapy

We are studying a new oncolytic virus treatment combined with chemotherapy for patients with melanoma. This trial aims to see if this combination can improve treatment outcomes.

Melanoma>2 yearsSafety phase (I)DermatologyOncology

Chronic Lymphocytic Leukemia: Mosunetuzumab and Pirtobrutinib Combination

We are studying the safety and effectiveness of combining two medications for patients with relapsed or refractory chronic lymphocytic leukemia. This research aims to understand how well the body responds to this treatment.

Relapsed or Refractory Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Systemic Lupus Erythematosus: GSK4527363 Study

We are investigating a new treatment for systemic lupus erythematosus in healthy individuals and those with the condition. The study includes participants from Chinese and Japanese backgrounds to see how the treatment works across different groups.

Systemic Lupus Erythematosus1-2 yearsSafety phase (I)Rheumatology

Advanced Solid Tumors: BGB-B3227 and Tislelizumab

We are testing a new treatment combining BGB-B3227 with Tislelizumab for patients with advanced or metastatic solid tumors. This study aims to understand how effective this combination may be in treating their condition.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

Spinal Muscular Atrophy: Nusinersen via ThecaFlex DRx System

We are studying how the body processes nusinersen when given through the ThecaFlex DRx system in adults and children with spinal muscular atrophy. This research aims to compare it to the standard delivery method.

Spinal Muscular Atrophy1-2 yearsSafety phase (I)No PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for people with untreated advanced esophageal cancer. The goal is to see if it is safe and effective compared to standard options.

Esophageal Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesOncology

Borderline Personality Disorder and ADHD: BI 3031185 Study

We are testing how well BI 3031185 is tolerated by individuals with borderline personality disorder or ADHD. This study aims to gather information on its safety and side effects.

Borderline Personality DisorderAttention Deficit Hyperactivity Disorder6-12 monthsSafety phase (I)Psychiatry

Acute Spinal Cord Injury: NG004 Treatment

We are testing a new antibody treatment for patients with acute spinal cord injuries to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Cervical Spinal Cord InjurySafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cancer Treatment: ABP 234 vs. Keytruda

We are comparing a new treatment called ABP 234 with Keytruda for patients with cancer. This study aims to see which option may be more effective in managing the disease.

Advanced Non-Squamous Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology